AUTHORS
Zilu Zhang, MD, Yeqian Zhao2, Yigeng Cao II, MD, PhD3, Wenhui Gao, MD4, Yuqing Tu5, Jiayu Liu6, Miao Miao7, Chupeng Zhang8, Qi Wen, MD9, Jie Ji, MD10, Rong Guo, MD11, Weijie Cao12, Hongru Chen, PhD13, Ruoxuan Zhang Jr14, Kourong Miao15, Zhenfang Liu16, Hua Jin17, Xiao-Dong Mo, MD18, Wei Shi19, Yang Cao, MD20, Jiong Hu, MD21, Yanmin Zhao, MD22, Jia Chen, PhD23, Xianmin Song, PhD24, Er-Lie Jiang, MD25, Xiaoxia Hu, MD26
AFFILIATIONS
1 Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
2 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
3 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
4 Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
5 Department of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
6 Shanghai General Hospital, Shanghai, China
7 Department of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
8 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
9 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
10 West China Hospital, Chengdu, China
11 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
12 The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
13 Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
14 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
15 The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
16 The First Affiliated Hospital of Guangxi Medical University, Nanning, China
17 Department of Hematology, Nanfang Hospital, Southern Medical University, Guangzhou, China
18 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China
19 Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
20 Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
21 Shanghai Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
22 Bone Marrow Transplantation Center, The First Affiliated Hospital & Liangzhu Laboratory, Zhejiang University School of Medicine, Hangzhou, China
23 Department of Hematology, National Clinical Research Center for Hematologic Diseases, The First Affiliated Hospital of Soochow University, Suzhou, China
24 Shanghai General Hospital, Shanghai, China
25 State Key Laboratory of Experimental Hematology and National Clinical Research Center for Blood Diseases, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
26 State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Introduction: Allogeneic hematopoietic cell transplantation (allo-HCT) remains the only potentially curative treatment for myelodysplastic neoplasms (MDS). However, currently available prognostic systems have limited applicability after transplantation because disease-based models lack transplant-related information, whereas transplant-specific models were developed before widespread incorporation of molecular profiling. We therefore developed MDS-HCT, an integrated molecular-transplant model for individualized prediction of overall survival (OS) and externally evaluated it in an independent multicenter validation cohort.
Methods: This multicenter retrospective study included consecutive patients with MDS undergoing first allo-HCT at 13 centers between January 2019 and April 2025. Patients from 11 centers comprised the training cohort, and patients from 2 independent centers comprised the external validation cohort. Candidate variables included disease characteristics, molecular features, patient-related factors, and transplant-related variables. The final model was developed using Cox regression approaches and internally validated by 10-fold cross-validation. Performance was assessed using Harrell’s C-index, time-dependent area under the curve (AUC), calibration, and comparison with existing models including IPSS-M, EBMT, CIBMTR, and Kröger models.
Results: The training and external validation cohorts included 1,002 and 592 patients, respectively. Three-year OS was 77.9% (95% CI, 75.3%–80.6%) in the training cohort and 75.9% (95% CI, 72.4%–79.6%) in the external validation cohort. The corresponding 3-year cumulative incidences of non-relapse mortality (NRM) and relapse were 14.2% and 14.4% in training, and 16.9% and 11.5% in external validation, respectively. The final MDS-HCT model incorporated pre-HCT treatment strategy, patient age, transplant conditioning intensity (TCI) score, donor type, multi-hit TP53 and/or complex karyotype (CK), pre-HCT IPSS-M category, Hematopoietic Cell Transplantation-specific Comorbidity Index (HCT-CI), and conditioning regimen classified as myeloablative conditioning (MAC) or reduced-intensity conditioning (RIC). Based on reductions in likelihood ratio chi-square statistics, HCT-CI and TCI contributed most strongly to the model, followed by multi-hit TP53 and/or CK. In the training cohort, the model achieved a C-index of 0.704 (95% CI, 0.669–0.739), with 1-, 2-, and 3-year AUCs of 0.728, 0.752, and 0.733, respectively. Ten-fold cross-validation yielded a C-index of 0.679 and corresponding AUCs of 0.701, 0.724, and 0.705. Calibration showed acceptable agreement between predicted and observed OS at 1, 2, and 3 years. To facilitate clinical application, the final model was translated into a nomogram. Score cutoffs of 66.3 and 111.1 points, corresponding to the 25th and 85th percentiles of the score distribution in the training cohort, defined low-, intermediate-, and high-risk groups. In the training cohort, 3-year OS rates were 93.9% (95% CI, 90.7%–97.2%), 77.5% (95% CI, 74.0%–81.3%), and 49.3% (95% CI, 41.2%–59.1%), respectively (P < 0.001). Relapse and NRM also differed significantly across the three risk groups (both P < 0.001). The locked model was applied to the external validation cohort without refitting or recalibration, achieving a C-index of 0.686 (95% CI, 0.643–0.728) and 1-, 2-, and 3-year AUCs of 0.717, 0.733, and 0.717. Applying the same nomogram cutoffs without modification reproduced clear risk separation, with 3-year OS rates of 94.0% (95% CI, 90.3%–97.9%), 71.3% (95% CI, 66.1%–76.9%), and 49.7% (95% CI, 39.1%–63.1%), respectively (P < 0.001). In the external validation cohort, MDS-HCT showed higher discrimination than IPSS-M, EBMT model, CIBMTR model, and the Kröger model, with C-indices of 0.686, 0.531, 0.567, 0.588, and 0.628, respectively.
Conclusions: MDS-HCT integrates molecular, clinical, and transplantation-related determinants to provide individualized prognostic stratification after allo-HCT. External validation demonstrated reproducible performance and superior discrimination compared with existing disease- and transplant-specific models. This model may facilitate personalized risk assessment and treatment decision-making for patients with MDS undergoing allo-HCT.
DISCLOSURES
Zilu Zhang, MD: No relevant conflicts of interest to declare.